Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Rises By 623.6%

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a large increase in short interest in January. As of January 30th, there was short interest totaling 260,110 shares, an increase of 623.6% from the January 15th total of 35,947 shares. Based on an average daily volume of 11,506,003 shares, the short-interest ratio is presently 0.0 days. Currently, 4.3% of the shares of the stock are sold short. Currently, 4.3% of the shares of the stock are sold short. Based on an average daily volume of 11,506,003 shares, the short-interest ratio is presently 0.0 days.

Aprea Therapeutics Stock Performance

NASDAQ APRE opened at $0.64 on Wednesday. The business has a fifty day moving average price of $0.87 and a 200 day moving average price of $1.26. The company has a market cap of $4.47 million, a P/E ratio of -0.30 and a beta of 1.48. Aprea Therapeutics has a one year low of $0.55 and a one year high of $3.72.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Wednesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.36). The business had revenue of $0.00 million for the quarter. Aprea Therapeutics had a negative return on equity of 88.12% and a negative net margin of 2,666.46%. As a group, sell-side analysts predict that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Analyst Ratings Changes

APRE has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $4.00 price objective (down from $5.00) on shares of Aprea Therapeutics in a research report on Thursday, January 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Zacks Research cut shares of Aprea Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Finally, Wedbush decreased their price objective on shares of Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $5.50.

Insider Buying and Selling at Aprea Therapeutics

In other Aprea Therapeutics news, Director Marc Duey purchased 21,459 shares of Aprea Therapeutics stock in a transaction that occurred on Wednesday, December 10th. The stock was bought at an average price of $1.17 per share, with a total value of $25,107.03. Following the acquisition, the director owned 256,155 shares of the company’s stock, valued at $299,701.35. This trade represents a 9.14% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 13.63% of the stock is currently owned by corporate insiders.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.